Suppr超能文献

破坏 CCT-β:β-微管蛋白通过激活 MAPKs 选择性杀死 CCT-β 过表达的癌细胞。

Disrupting CCT-β : β-tubulin selectively kills CCT-β overexpressed cancer cells through MAPKs activation.

机构信息

Institute of Biological Chemistry, Academia Sinica, Taipei 11529, Taiwan, ROC.

Graduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, Taipei 11031, Taiwan, ROC.

出版信息

Cell Death Dis. 2017 Sep 14;8(9):e3052. doi: 10.1038/cddis.2017.425.

Abstract

We have previously demonstrated the ability of I-Trp to disrupt the protein-protein interaction of β-tubulin with chaperonin-containing TCP-1β (CCT-β). This caused more severe apoptosis in multidrug-resistant MES-SA/Dx5, compared to MES-SA, due to its higher CCT-β overexpression. In this study, we screened a panel of cancer cell lines, finding CCT-β overexpression in the triple-negative breast cancer cell line MDA-MB-231, colorectal cancer cell lines Colo205 and HCT116, and a gastric cancer cell line MKN-45. Thus, I-Trp killed these cancers with sub- to low-μM EC, whereas it was non-toxic to MCF-10A. We then synthesized analogs of I-Trp and evaluated their cytotoxicity. Furthermore, apoptotic mechanism investigations revealed the activation of both protein ubiquitination/degradation and ER-associated protein degradation pathways. These pathways proceeded through activation of MAPKs at the onset of CCT-β : β-tubulin complex disruption. We thus establish an effective strategy to treat CCT-β overexpressed cancers by disrupting the CCT-β : β-tubulin complex.

摘要

我们之前已经证明了 I-Trp 能够破坏β-微管蛋白与含伴侣蛋白的 TCP-1β(CCT-β)的蛋白质-蛋白质相互作用。由于其 CCT-β过表达,与 MES-SA 相比,在多药耐药的 MES-SA/Dx5 中引起更严重的细胞凋亡。在这项研究中,我们筛选了一组癌细胞系,发现三阴性乳腺癌细胞系 MDA-MB-231、结直肠癌细胞系 Colo205 和 HCT116 以及胃癌细胞系 MKN-45 中存在 CCT-β过表达。因此,I-Trp 以亚至低μM 的 EC 杀死了这些癌症,而对 MCF-10A 则没有毒性。然后,我们合成了 I-Trp 的类似物并评估了它们的细胞毒性。此外,凋亡机制研究揭示了蛋白泛素化/降解和 ER 相关蛋白降解途径的激活。这些途径通过在 CCT-β:β-微管蛋白复合物破坏时 MAPKs 的激活而进行。因此,我们通过破坏 CCT-β:β-微管蛋白复合物建立了一种有效治疗 CCT-β过表达癌症的策略。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验